The FDA approval of the PARP inhibitor olaparib for fourth-line therapy of germline BRCA1/2-mutated ovarian cancer represents the first registered indication for this class of drugs in any disease. PARP is a family of proteins involved in the repair of single-strand DNA breaks. High-grade serous ovarian carcinomas with BRCA deficiencies may be particularly vulnerable to both direct and indirect...

(Abstracted from J Clin Oncol 2022; doi: 10.1200/JCO.22.01549) Because of nonspecific symptoms at disease presentation and inadequate screening methods, ovarian cancer is often advanced the time diagnosis results in a 10-year survival 17% patients with epithelial cancer. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib new standard care newly diagnosed BRCA1 and/or BRCA2 (BRCA) mutation.

BACKGROUND A comprehensive body of evidence has shown that aspirin has cancer-preventive effects, particularly against gastrointestinal cancer, but its effects on the risk of ovarian cancer are less well established. This nationwide case-control study examined the association between low-dose aspirin and the risk of ovarian cancer. PATIENTS AND METHODS We identified all patients in the Danish...

Introduction Primary carcinoma of the ovary is the fourth most common cancer among women in the UK; there were almost 7000 new cases reported in 1999, which equates to a lifetime risk for women of 2%. In addition, ovarian cancer is the fifth most common cause of deaths in women, with more than 4500 deaths from the disease every year.1 The natural history of ovarian cancer development, including...

Chemoresistance is a major hurdle in the management of patients with epithelial ovarian cancer and is responsible for its high mortality. Studies have shown that chemoresistance is due to the presence of a subgroup of cancer cells with stemness properties and a high capacity for tumor repair. We have developed a library of super-benzopyran analogues to generate potent compounds that can induce ...

Few studies have evaluated Hedgehog (Hh) signaling pathway activation in different types of ovarian tumors including benign, borderline and malignant ovarian tumors. The present study investigated the expression of Hh signaling pathway components (SHH, SMO, PTCH, and GLI1) in 193 ovarian epithelial tumor specimens (including 147 malignant epithelial ovarian cancers, 30 borderline ovarian tumors...

OBJECTIVE The objective of this study was to identify the prognostic factors of secondary cytoreductive surgery on survival in patients with recurrent epithelial ovarian cancer. METHODS The medical records of all patients who underwent secondary cytoreductive surgery between May 2001 and October 2007 at the National Cancer Center, Korea were reviewed. Univariate and multivariate analyses were...